Please login to the form below

Not currently logged in
Email:
Password:

Teva's US approval for hypertension drugs

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure drugs Cozaar and Hyzaar

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure (hypertension) drugs Cozaar (losartan) and Hyzaar (hydrochlorothiazide and losartan), and intends to launch sales immediately.

Teva, the world's biggest generic drug producer, will have 180 days to market the generics exclusively, an award generally given to companies that challenge patents first.

An exclusivity period can allow generic companies a window of significant sales before rivals rush in and pricing freefalls.

Teva said a federal appeals court this week rejected an effort by generic drug producers Apotex and Roxane Laboratories to challenge Teva's right to that exclusivity period.

Last week, Apotex and Roxane sued the US Food and Drug Administration, arguing that a key patent for the drugs had expired and therefore no company was eligible for the exclusive rights.

Cozaar and Hyzaar, which have annual US sales of about $1.6bn, have been among Merck's biggest selling products, but the pharma company has been bracing for generic competition this year.

8th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Innovation and agility
Start small but think big
Exploring the potential of agility in unlocking creativity...
The Pivot
In times of uncertainty it is critical for businesses to take action to protect their brand image and longevity....
Peter Jackson
The global antibiotic crisis: a 2020 perspective
A report from the CDC says the ‘approaching’ post-antibiotic era is already here...

Infographics